Zhongxin Capital
中新资本
Zhongxin Capital (中新资本) is a Chinese venture capital fund that appears as a co-investor in early-stage deals, particularly in biotech and hard tech. The fund has participated in rounds alongside more prominent names: it co-led Shize Biotech's round with Qiming Venture Partners, Lilly Asia Ventures, and Jinyuan Zhanhong in late 2022 , and followed in Qiheshengke Biotechnology's over-100-million-yuan Pre-A round led by Chende Capital in April 2023 , as well as N1 Life's pre-A round led by Legend Capital in mid-2023 .
elsewhere's corpus does not cover Zhongxin Capital's own founding, team, or fund size in detail — the above is drawn from its appearance as a named participant in other firms' deal announcements.
AI-generated — may contain errors, please verify.
Coverage
From Angel to G+ Round: 5 Early-Stage FreeS Fund Portfolio Companies Raise Over 3 Billion RMB | FreeS Family Funding News · Vol 14
Looking forward to working alongside more outstanding founders.
Chip/Consumer Electronics/Gene Editing Firms Raise New Funding; Quantum Computers, Micro-Display Chips Achieve Global Leadership | Rongbao · April
Targeting international advanced standards.
Qihe Biotech Closes Over 100 Million Yuan Pre-A Round to Accelerate Development and Application of Novel Gene-Editing Technologies
Accelerate the commercialization of gene-edited breeding.
Qiheshengke Biotechnology Raises Over 100 Million RMB in Pre-A Round with Source Code Capital Participation
This round of funding will help Qiheshengke Biotechnology accelerate the commercialization of gene-edited bio-breeding.
Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
